SCHEMBL84806

SCHEMBL84806

CCCC(=O)N1CCCCC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.73
MEN1 O00255 3/20 0.73
KMT2A Q03164 3/20 0.73
TDP1 Q9NUW8 3/20 0.73
ATM Q13315 1/20 0.62
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
CHRNB2 P17787 1/20 0.48
CHRNA3 P32297 1/20 0.48
CHRNA4 P43681 1/20 0.48
CHRNB3 Q05901 1/20 0.48
CHRNA6 Q15825 1/20 0.48
GAA P10253 1/20 0.46
HPGD P15428 3/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
NPC1 O15118 1/20 0.46
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3839653 1.00 L3MBTL1 (0.73) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL805464 0.98 L3MBTL1 (0.72) L3MBTL1MEN1KMT2ATDP1ATM
Hydrochloric Acid SCHEMBL28021541 0.95 L3MBTL1 (0.69) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL9762642 0.93
SCHEMBL10663507 0.87 L3MBTL1 (0.58) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL674671 0.87
SCHEMBL10534153 0.86 L3MBTL1 (0.88) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL7837034 0.86 L3MBTL1 (0.88) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL150076 0.86 L3MBTL1 (0.88) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL10535931 0.85 L3MBTL1 (1.00) L3MBTL1MEN1KMT2ATDP1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476448-A2 AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-11-17 EP claimed
WO-2003070731-A2 AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO claimed
WO-2026087386-A1 ROSIN DIESTER COMPOUNDS AND USES THEREOF FIRMENICH SA (CH) 2026-04-30 WO disclosed
EP-4661972-A1 TASTE-MODIFYING COMPOSITIONS AND USES THEREOF Firmenich SA (CH) 2025-12-17 EP disclosed
US-12291512-B2 Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor NXERA PHARMA UK LIMITED (GB) 2025-05-06 US disclosed
WO-2025078256-A1 COMPOSITION GIVAUDAN SA (CH) 2025-04-17 WO disclosed
EP-4476211-A1 ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2024-12-18 EP disclosed
EP-4452253-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD The Katholieke Universiteit Leuven (BE) 2024-10-30 EP disclosed
WO-2024200399-A1 TASTE-MODIFYING COMPOSITIONS AND USES THEREOF FIRMENICH SA (CH) 2024-10-03 WO disclosed
US-20240308989-A1 PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS ORION CORP (FI) 2024-09-19 US disclosed
US-12029739-B2 SHP2 inhibitor and use thereof KANAPH THERAPEUTICS INC. (KR) 2024-07-09 US disclosed
EP-0089908-A1 Process for producing carboxylic-acid anhydrides RHONE-POULENC CHIMIE DE BASE (FR) 1983-09-28 EP disclosed
EP-0050084-A1 Preparation of carboxylic-acid anhydrides by carbonylation RHONE-POULENC CHIMIE DE BASE (FR) 1982-04-21 EP disclosed
EP-0018927-B1 PROCESS FOR PREPARING CARBOXYLIC ACIDS BY CARBONYLATION RHONE-POULENC CHIMIE DE BASE (FR) 1982-02-24 EP disclosed
US-4234484-A FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID HOECHST AKTIENGESELLSCHAFT (DE) 1980-11-18 US disclosed
EP-0018927-A1 Process for preparing carboxylic acids by carbonylation RHONE-POULENC CHIMIE DE BASE (FR) 1980-11-12 EP disclosed
US-4149941-A ELECTROLYTIC ALKOXYLATION HOECHST AKTIENGESELLSCHAFT (DE) 1979-04-17 US disclosed
US-4118500-A Fungicidal alkoxy mono- and dialkoxy N-substituted cyclic amines HOECHST AKTIENGESELLSCHAFT (DE) 1978-10-03 US disclosed
US-4090024-A Process for the production of skatylhydantoin DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) 1978-05-16 US disclosed
US-3960844-A Preparation of 6-acylamino-2-methyl-2-halomethyl penams ELI LILLY AND COMPANY (US) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12291512-B2 Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor CHRM1, CHRM2, CHRM4 L3MBTL1 2861/4885MEN1 920/4885KMT2A 2379/4885
US-12029739-B2 SHP2 inhibitor and use thereof PTPN1, PTPN5, PTPN2 L3MBTL1 2970/4885MEN1 3025/4885KMT2A 1019/4885
US-20240308989-A1 PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS CYP11B1, CYP11B2, CYP4A11 L3MBTL1 1781/4885MEN1 1007/4885KMT2A 3526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.